LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

Search

Catalyst Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

24.08 -1.07

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

23.79

Massimo

24.35

Metriche Chiave

By Trading Economics

Entrata

801K

57M

Vendite

-399K

141M

P/E

Media del settore

15.688

54.533

EPS

0.68

Margine di Profitto

40.119

Dipendenti

181

EBITDA

526K

73M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+39.8% upside

Dividendi

By Dow Jones

Utili prossimi

6 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-25M

3B

Apertura precedente

25.15

Chiusura precedente

24.08

Notizie sul Sentiment di mercato

By Acuity

20%

80%

34 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Catalyst Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 mag 2025, 23:48 UTC

Azioni calde

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22 mag 2025, 23:07 UTC

Notizie principali

Fortescue Energy CEO to Resign in Executive Overhaul

22 mag 2025, 23:03 UTC

I principali Market Mover

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22 mag 2025, 23:59 UTC

Discorsi di Mercato

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22 mag 2025, 23:45 UTC

Discorsi di Mercato

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22 mag 2025, 23:45 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

22 mag 2025, 23:23 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

22 mag 2025, 23:23 UTC

Discorsi di Mercato

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22 mag 2025, 20:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

22 mag 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

22 mag 2025, 20:46 UTC

Acquisizioni, Fusioni, Takeovers

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22 mag 2025, 20:39 UTC

Utili

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22 mag 2025, 20:36 UTC

Notizie principali

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22 mag 2025, 20:36 UTC

Notizie principali
Utili

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22 mag 2025, 20:32 UTC

Notizie principali
Utili

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 mag 2025, 20:27 UTC

Notizie principali

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22 mag 2025, 20:20 UTC

Notizie principali

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 mag 2025, 20:17 UTC

Notizie principali

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22 mag 2025, 20:16 UTC

Utili

Intchains Group 1Q Rev $18.2M >ICG

22 mag 2025, 20:15 UTC

Notizie principali

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 mag 2025, 20:08 UTC

Notizie principali
Utili

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 mag 2025, 20:05 UTC

Notizie principali

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22 mag 2025, 20:04 UTC

Utili

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22 mag 2025, 20:04 UTC

Utili

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22 mag 2025, 20:01 UTC

Utili

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22 mag 2025, 20:01 UTC

Utili

Workday 1Q Net $68M >WDAY

22 mag 2025, 20:01 UTC

Utili

Workday 1Q EPS 25c >WDAY

22 mag 2025, 20:01 UTC

Utili

Workday 1Q Adj EPS $2.23 >WDAY

22 mag 2025, 20:01 UTC

Utili

Workday 1Q Subscription Revenue $2.06B >WDAY

22 mag 2025, 20:01 UTC

Utili

Workday 1Q Rev $2.24B >WDAY

Confronto tra pari

Modifica del prezzo

Catalyst Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

39.8% in crescita

Previsioni per 12 mesi

Media 34 USD  39.8%

Alto 40 USD

Basso 31 USD

Basato su 7 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Catalyst Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

7 ratings

7

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

N/A / 24.28Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Bullish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

34 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.